PT - JOURNAL ARTICLE AU - Djataou, Patrice AU - Djuidje, Marceline Ngounoue AU - Nguefack-Tsague, Georges AU - de Dieu Anoubissi, Jean AU - Kameni, Joel Kadji AU - Tiga, Aline AU - Elong, Elise AU - Djaouda, Moussa AU - Ndjolo, Alexis AU - Nkenfou, Céline Nguefeu TI - Trend of new cases of Human Immunodeficiency Virus infections in two health facilities in the Northern Cameroon between 2021-2022 AID - 10.1101/2024.04.10.24305613 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.10.24305613 4099 - http://medrxiv.org/content/early/2024/04/12/2024.04.10.24305613.short 4100 - http://medrxiv.org/content/early/2024/04/12/2024.04.10.24305613.full AB - HIV/AIDS continues to be a global public health problem. Studies of the incidence and prevalence of HIV and other sexually transmitted infections (STIs) that may contribute to or aggravate its acquisition remain an effective means of prevention. In recent years, terrorist groups have established themselves in the northern regions of Cameroon. This insecurity has led to a large influx of refugees with no information about their HIV and STI status. Given this above mentioned situation, this study aimed to assess the incidence and prevalence of HIV and STI and their associated risk factors in order to adjust strategies to monitor the epidemic. A cohort of 684 consenting participants from the North and Far North were enrolled in the study in 2021 and followed up in 2022 to measure the incidence and prevalence of HIV and to assess some associated risk factors. Each participant was administered a pretested questionnaire to collect sociodemographic variables and risk behaviors. Anti-HIV Ab, HBsAg (Hepatitis B Surface Antigen), TPHA (Treponema Pallidum Hemagglutination Assay) tests were performed. The data were compiled using EPI Info 7.5.2 for epidemiological analyses. The association between co-infections of HIV, Hepatitis, and syphilis and HIV incidence was evaluated using the Chi-2 test. The HIV incidence and overall prevalence were 1.63% (163/10,000 population) and 3.8%, respectively. The HIV incidence increased from 0.27% in 2017 (DHS) to 1.63% in the North and Far North regions as found in our study. The incidences of syphilis and hepatitis B were 1.03% and 4.56%, respectively. Factors associated with HIV acquisition included religion (Muslims being more infected, P<0.03), unprotected sex with a new partner (P<0.007), having a sex worker as a partner (P<0.0001), and co-infection with syphilis and hepatitis B (P<0.05). The findings also link increased HIV incidence to insecurity and population displacement. In HIV prevention strategies, it is important to consider the security and political stability context as well as HIV-associated infections such as hepatitis B and syphilis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCameroon Government, through the Chantal Biya International Reference Centre. The funder play no role in the projectAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the hospitals and the National Ethics Committee for Human Health in Cameroon (N°2021/06/85/CE/CNRESH/SP). Recruited participants agreed to participate in the study and signed the informed consent form after reading and understanding it.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableData collected are fully available and presented in the manuscript.